After Frontline Immunotherapy Fails: Panel Maps Next Moves in Melanoma

Immune checkpoint inhibitors have transformed frontline care for metastatic melanoma, yet a substantial proportion of patients never achieve durable disease control — and that gap defines one of the sharpest unmet needs in the field today. A panel of clinicians recently examined how treatment decisions unfold once frontline immunotherapy stops working, and their discussion sketches a practical sequencing framework for the post-progression setting.

What options exist after frontline immunotherapy fails?

For patients with BRAF-mutant disease, BRAF/MEK inhibitors remain an available next step. That much is straightforward. The harder question is timing.

The faculty note that durable benefit with targeted therapy is uncommon. In practice, that means several panelists prefer to hold these agents in reserve. They deploy BRAF/MEK inhibition only when the clinical picture demands a fast response — rapid progression, declining performance status, or a rising symptom burden.

The logic is simple. Targeted therapy buys control, but rarely buys years. Immunotherapy, by contrast, can produce responses that hold.

How does the frontline regimen shape the next step?

The panel highlights that the choice of first-line therapy is not a closed chapter; it directly constrains what comes second.

Patients who received nivolumab plus relatlimab in the frontline setting may be considered for ipilimumab plus nivolumab before moving to more intensive options. That sequencing keeps the patient within the checkpoint inhibitor class while escalating from the LAG-3–based doublet to the CTLA-4–based combination.

Fit patients, meanwhile, may move toward cellular therapy. Here targeted agents find a second role: the panel describes BRAF/MEK inhibition serving as a bridge when needed — a way to stabilize disease while a patient is being prepared for a more intensive cellular approach.

Three pathways emerge from the discussion:

• Reserve targeted therapy for rapid progression, declining performance status, or rising symptom burden in BRAF-mutant disease
• Escalate within immunotherapy, moving from nivolumab plus relatlimab to ipilimumab plus nivolumab
• Pursue cellular therapy in fit patients, with targeted agents used as a bridge

Why does the panel keep steering back to clinical trials?

The panel repeatedly emphasizes clinical trial enrollment in the post-progression setting. The reasoning is rooted in durability: responses to immunotherapy tend to outlast responses to targeted agents.

That durability gap is the thread running through the entire discussion. It explains why the faculty resist reaching early for BRAF/MEK inhibition in patients who could still derive lasting benefit from an immunotherapeutic approach, and why trials — which frequently test new immunotherapy combinations or cellular strategies — represent the preferred route when standard options narrow.

The takeaway for clinicians: sequence deliberately, spend targeted therapy only when speed matters, and treat the trial portfolio as a core part of the post-progression pathway rather than a fallback.

What is the broader picture?

Frontline immune checkpoint inhibition has redefined metastatic melanoma care, but it has also created a growing population of patients whose disease escapes control. Each of those progressions forces a decision the field has not fully standardized.

The panel's framework — reserve BRAF/MEK inhibitors for urgency, escalate from nivolumab plus relatlimab to ipilimumab plus nivolumab, route fit patients toward cellular therapy, and default to trials — offers a workable map of that territory. As cellular therapies and next-generation immunotherapy combinations mature, the post-progression pathway in metastatic melanoma is likely to keep shifting toward earlier, more durable interventions.